Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 15, 2026, 9:29 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 2,426 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: 0.9 % sodium chloride Clear all
Not yet recruiting Phase 1 Interventional Accepts healthy volunteers

Phase I Study of VLPDEN-02 Dengue Vaccine in Healthy Adults

NCT07831473
View directory record Official record
Conditions
Randomised Clinical Trial, Double Blind, Dengue, Challenge Test, Dose Escalation and Safety
Interventions
VLPDEN-02 1.0 µg (0.25 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 10 µg (2.5 µg of each VLP) + ALFQ adjuvant, VLPDEN-02 100 µg (25 µg of each VLP) + ALFQ adjuvant, ALFQ adjuvant + Saline, rDEN3Delta30
Biological
Lead sponsor
VLP Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2027 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Glucagon Administration on Energy Expenditure

NCT02237053
View directory record Official record
Conditions
Hyperglucagonemia, Obesity
Interventions
Glucagon, Octreotide, Placebo, Insulin
Drug · Behavioral
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
18 Years to 50 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Apr 26, 2018 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 4 Interventional Results available

Intraoperative Infusion of Precedex to Reduce Length of Stay After Lumbar Spine Fusion

NCT00808665
View directory record Official record
Conditions
Spinal Fusion Acquired, Spinal Stenosis, Lesions of Lumbosacral Intervertebral Disc, Spinal Diseases
Interventions
Dexmedetomidine, 0.9% Saline
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 25, 2018 · Synced Oct 15, 2026, 9:29 AM EDT
Not listed Not applicable Interventional

Efficacy of IV Acetaminophen in Acute Post-Operative Pain Control in Laparoscopic Roux-en-Y Gastric Bypass Surgery (LRYGBP) Patients

NCT01460667
View directory record Official record
Conditions
Morbid Obesity
Interventions
IV acetaminophen, IV normal saline
Drug
Lead sponsor
McLaren Regional Medical Center
Other
Eligibility
18 Years to 65 Years
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2011
U.S. locations
1
States / cities
Flint, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 27, 2011 · Synced Oct 15, 2026, 9:29 AM EDT
Terminated Phase 4 Interventional Results available

Pain With Trigger Finger Injection: A Comparison of Steroid Alone Versus Steroid/Lidocaine Mixture

NCT02421419
View directory record Official record
Conditions
Trigger Finger Disorder
Interventions
Dexamethasone Sodium Phosphate, Xylocaine, Sodium Chloride
Drug
Lead sponsor
Kenneth Taylor, M.D.
Other
Eligibility
18 Years to 90 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 28, 2018 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 1 Interventional

A Dose Escalation Study of Intranasal Neuropeptide Y in Post Traumatic Stress Disorder (PTSD)

NCT01533519
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Neuropeptide Y
Drug
Lead sponsor
James Murrough
Other
Eligibility
18 Years to 60 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2016 · Synced Oct 15, 2026, 9:29 AM EDT
Terminated Phase 4 Interventional Results available

Tranexamic Acid for Craniofacial Surgery

NCT00722436
View directory record Official record
Conditions
Craniosynostosis, Bleeding
Interventions
Tranexamic acid, saline
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 18 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 15, 2017 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Results available

Randomized, Double-Blind Clinical Trial for Parkinson's Disease (Early and Moderate)

NCT04928287
View directory record Official record
Conditions
Parkinson Disease
Interventions
HB-adMSCs, Placebo
Biological · Other
Lead sponsor
Hope Biosciences Research Foundation
Industry
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Sugar Land, Texas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Oct 15, 2026, 9:29 AM EDT
Withdrawn Phase 2 Interventional

Valproic Acid (VPA) for Acute Kidney Injury (AKI) in Liver Transplant Patients

NCT04531592
View directory record Official record
Conditions
Acute Kidney Injury, Ischemia Reperfusion Injury
Interventions
Valproic acid, Isotonic saline solution
Drug
Lead sponsor
Westat
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
4
States / cities
San Francisco, California • Denver, Colorado • Dallas, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2021 · Synced Oct 15, 2026, 9:29 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

RM1 Project 1 - tAN Naloxone

NCT05490134
View directory record Official record
Conditions
Analgesia
Interventions
Naloxone, Saline
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 65 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

NCT02915016
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2022 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Pain Management Following TRAM Flap for Breast Reconstruction

NCT00500565
View directory record Official record
Conditions
Breast Cancer
Interventions
Saline, Bupivicaine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2013 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Exenatide for Smoking Cessation and Prevention of Weight Gain

NCT05610800
View directory record Official record
Conditions
Smoking Cessation, Weight Gain
Interventions
Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 75 Years
Enrollment
140 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 23, 2026 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Inflammation and Threat Sensitivity in PTSD

NCT03048929
View directory record Official record
Conditions
Posttraumatic Stress Disorder
Interventions
Typhoid Vi Polysaccharide Vaccine, Placebo
Biological
Lead sponsor
University of California, San Francisco
Other
Eligibility
30 Years to 60 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
2
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 13, 2021 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Not applicable Interventional

Saline Hypertonic in Preschoolers

NCT02378467
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
7% Hypertonic Saline (HS), 0.9% Isotonic Saline (IS)
Drug
Lead sponsor
University of Washington, the Collaborative Health Studies Coordinating Center
Other
Eligibility
3 Years to 5 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
23
States / cities
Birmingham, Alabama • Palo Alto, California • Aurora, Colorado + 20 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 15, 2026, 9:29 AM EDT
Active, not recruiting Phase 3 Interventional

A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)

NCT07037771
View directory record Official record
Conditions
Homozygous Familial Hypercholesterolemia
Interventions
zodasiran Injection, Placebo
Drug
Lead sponsor
Arrowhead Pharmaceuticals
Industry
Eligibility
12 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
4
States / cities
Park Ridge, Illinois • New York, New York • Cincinnati, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

The Autonomic Nervous System and the Metabolic Syndrome

NCT00580957
View directory record Official record
Conditions
Obesity
Interventions
Blocked, Intact
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 60 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 5, 2016 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 3 Interventional

Re-EValuating the Inhibition of Stress Erosions (REVISE) Trial

NCT03374800
View directory record Official record
Conditions
Gastrointestinal Hemorrhage (Clinically Important, Upper)
Interventions
Placebo (0.9% saline), Pantoprazole
Drug
Lead sponsor
McMaster University
Other
Eligibility
18 Years and older
Enrollment
4,800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Immunogenicity Of A Recombinant H5N1 Vaccine In Adults

NCT01250795
View directory record Official record
Conditions
Healthy
Interventions
HAI-05 Influenza Vaccine, Saline
Biological · Other
Lead sponsor
Fraunhofer, Center for Molecular Biotechnology
Industry
Eligibility
18 Years to 49 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
Wichita, Kansas • Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Comparison Study of the Tensile Strength of Sutures Used in Dermatologic Surgery on the Day of Suture Removal, Following Wound Care With Two Different Products

NCT01533675
View directory record Official record
Conditions
Sutured Wounds
Interventions
Hydrogen peroxide, Saline
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated May 10, 2017 · Synced Oct 15, 2026, 9:29 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Safety and Pharmacokinetics (PK) of a Polyurethane Tenofovir Disoproxil Fumarate (TDF) Vaginal Ring

NCT02006264
View directory record Official record
Conditions
HIV
Interventions
TDF Intravaginal Ring, Placebo Intravaginal Ring
Drug
Lead sponsor
Albert Einstein College of Medicine
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 28, 2018 · Synced Oct 15, 2026, 9:29 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety, Tolerability and Pharmacokinetics (PK) of GSK3732394 First-Time-in-Human (FTIH) Study

NCT03984812
View directory record Official record
Conditions
HIV Infections
Interventions
GSK3732394, Placebo
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 15, 2026, 9:29 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

NCT04851301
View directory record Official record
Conditions
Pain, Virtual Reality, Placebo, Temporomandibular Disorder
Interventions
Active Virtual Reality, sham Virtual Reality, No Intervention, Naloxone, Saline, Natural history
Behavioral · Other · Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
259 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 15, 2026, 9:29 AM EDT
Terminated Phase 2 Interventional

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

NCT04433546
View directory record Official record
Conditions
Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions
Pemziviptadil (PB1046), Low Dose (10 mg) Control
Drug
Lead sponsor
PhaseBio Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
4
States / cities
Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2020 · Synced Oct 15, 2026, 9:29 AM EDT